CliffBio
small molecule

OXALIPLATIN

OXALIPLATIN

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXALIPLATIN
Active ingredientOXALIPLATIN
Strength100MG/VIAL
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2010
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.